DUBLIN, January 4, 2022 / PRNewswire / – Endo International plc (NASDAQ: ENDP) today announced that one of its operating companies, Par Pharmaceutical, Inc. (Par), has started shipping the first generic version of CUVPOSA from Merz® (glycopyrrolate) 1 mg / 5 mL oral solution in the United States, following final approval by the United States Food and Drug Administration for its Abbreviated New Drug Application.
“We are proud to offer families a generic option of this important drug,” said Jon holden, Senior Vice President and General Manager, Generics at Endo. “Glycopyrrolate oral solution joins our broad portfolio of high-quality, low-cost generic products, and our reputation for reliable quality is a particularly critical factor when treating children. “
According to IQVIA™, CUVPOSA® sales were around $ 27 million for the past 12 months October 31, 2021.
CUVPOSA® is a registered trademark of Merz Pharmaceuticals, LLC.
Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best lives through the provision of quality life-enhancing therapies. Our decades of proven success come from passionate team members around the world who work together to deliver the best treatments. Together, we boldly transform knowledge into treatments that benefit those who need it, when they need it. Learn more at www.endo.com or connect with us on LinkedIn.
About Par Pharmaceutical
Par Pharmaceutical develops, manufactures and markets safe, innovative and cost-effective branded generic and injectable pharmaceuticals that help improve the quality of life for patients. Par, one of the leading generics industry leaders in the United States, has an expanding portfolio that includes sterile injectables, alternative dosage forms and other differentiated products. By Pharmaceutical is an Endo company. Learn more at www.parpharm.com.
Caution regarding forward-looking statements
Certain information contained in this press release may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities laws, including, but not limited to, statements. from Mr. Holden and any representations regarding product launch, shipments, sales potential, quality, safety or cost. Statements including words or expressions such as “believe”, “expect”, “anticipate”, “intend”, “estimate”, “plan”, “can”, “can”, “anticipate” “,” Intend “,” the future, “” potential “or similar expressions are forward-looking statements. All forward-looking statements contained in this press release reflect Endo’s current expectations regarding future events on the Company. based on trends and existing information and represent Endo’s judgment only as of the date of this press release. Actual results may differ materially and adversely from current expectations based on a number of factors affecting the business of Endo, including, but not limited to, the following: the outcome of our strategic review, contingency planning and any potential restructuring; the timing, impact or results of any pending or future litigation, investigation are or actual or contingent claims or liabilities, settlement discussions, negotiations or other adverse proceedings; our ability to satisfy judgments or settlements or pursue appeals, including bond requirements; our ability to adapt to changing market conditions; our ability to attract and retain key personnel; our inability to maintain financial covenants and operating obligations that would expose us to potential events of default on our outstanding debt; our ability to obtain additional debt or equity financing for working capital, capital expenditures, business development, debt service requirements, acquisitions or for general corporate or other purposes; our ability to refinance our debt; a significant reduction in our short- or long-term income that could prevent us from financing our operations and our liquidity needs or from repaying our debts. The occurrence or possibility of such an outcome has caused us to commit, and may result in further engagement in strategic reviews that may ultimately cause us to pursue one or more material business transactions or other corrective actions, including included as a preventive or proactive measure. These corrective actions could include a possible corporate reorganization, restructuring or bankruptcy involving all or part of our business, asset sales or other divestitures, cost reduction initiatives, corporate realignments. or strategic partnerships. Some of these measures may take a long time to implement and others may require the approval of a court or other third party. Such actions may be complex, could result in significant costs and charges or could otherwise have a negative impact on shareholder value, and there can be no assurance that we will be able to accomplish any of these alternatives on terms acceptable to them. us, or at all, or that they will result in the expected benefits. Therefore, the reader is cautioned not to rely on these forward-looking statements. Endo expressly disclaims any intention or obligation to update these forward-looking statements, except as required by law. Additional information regarding risk factors, including those referenced above, can be found in press releases issued by Endo, as well as in Endo’s public periodic filings with the United States Securities and Exchange Commission. and securities regulatory authorities in Canada, including the discussion under the heading “Risk Factors” in Endo’s most recent annual report on Form 10-K and any subsequent quarterly report on Form 10-Q or other documents filed with Securities and United States Exchange Commission.
SOURCE Endo International plc